{"generic":"Measles, Mumps, Rubella, and Varicella Vaccine, Live","drugs":["Measles, Mumps, Rubella, and Varicella Vaccine, Live","ProQuad"],"mono":{"0":{"id":"jwe0s0","title":"Generic Names","mono":"Measles, Mumps, Rubella, and Varicella Vaccine, Live"},"1":{"id":"jwe0s1","title":"Dosing and Indications","sub":{"1":{"id":"jwe0s1b5","title":"Pediatric Dosing","mono":"<ul><li>safety, immunogenicity, and efficacy not established in children less than 12 months of age<\/li><li><b>Measles-mumps-rubella vaccination - Varicella; Prophylaxis:<\/b> (12 months to 12 yr) 0.5 mL single dose SUBQ; at least 1 month and 3 months should elapse between repeat doses (if necessary) of measles- and varicella-containing vaccines, respectively; do not delay first dose past 15 months of age because of increased risk of postvaccination seizures.<\/li><\/ul>"},"3":{"id":"jwe0s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Measles-mumps-rubella vaccination - Varicella; Prophylaxis<br\/>"}}},"3":{"id":"jwe0s3","title":"Contraindications\/Warnings","sub":[{"id":"jwe0s3b9","title":"Contraindications","mono":"<ul><li>anaphylactic reaction to neomycin, history of<\/li><li>blood dyscrasias<\/li><li>concurrent immunosuppressive therapy, including high-dose systemic corticosteroid therapy<\/li><li>congenital or hereditary immunodeficiency, family history; unless immune competence is demonstrated<\/li><li>febrile illness, active, with fever higher than 38.5 degrees C (101.3 degrees F) (manufacturer); acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction (CDC)<\/li><li>HIV with severe immunocompromise (age-specific CD4+ T-lymphocyte less than 15%)<\/li><li>hypersensitivity to gelatin or any other component of the product<\/li><li>immunodeficiency, severe (eg, from hematologic and solid tumors, congenital immunodeficiency, long-term immunosuppressive therapy (prednisolone 20 mg or 2 mg\/kg daily or equivalent corticosteroid for 2 weeks or longer)) (CDC), immunodeficiency states, primary or acquired; including cellular immune deficiencies, HIV, AIDS, and hypogammaglobulinemic and dysgammaglobulinemic states (manufacturer)<\/li><li>lymphomas of any type, leukemia, or other malignant neoplasms affecting bone marrow or the lymphatic system<\/li><li>pregnancy<\/li><li>tuberculosis, active untreated<\/li><\/ul>"},{"id":"jwe0s3b10","title":"Precautions","mono":"<ul><li>anaphylactic or immediate hypersensitivity reaction after egg ingestion; live measles and live mumps vaccines are produced in chick embryo cell culture<\/li><li>antibody-containing products; blood or plasma transfusions or immune globulin administration within previous 11 months (specific interval depends on product) (CDC); blood or plasma transfusions or immune globulin administration within the previous 3 months; potential for interference with expected immune response (manufacturer)<\/li><li>cerebral injury, history of; febrile seizures have been reported following vaccination<\/li><li>concomitant chemotherapy or radiation therapy; live vaccine should not be administered for at least 3 months unless benefit outweighs risk of adverse reactions<\/li><li>convulsions, individual or family history; febrile seizures have been reported following vaccination<\/li><li>fever and febrile seizures occurring 5 to 12 days after vaccination; higher rate associated with dose 1 in pediatric patients 12 to 23 months of age with no prior vaccinations against measles, mumps, rubella, or varicella, nor previous history of the wild-type infections<\/li><li>medical conditions where stress due to fever should be avoided; vaccination may cause temperature elevations<\/li><li>recipients who have close contact with pregnant women who have not had chickenpox, newborn infants of mothers who have not had chickenpox, newborn infants born at less than 28 weeks of gestation (regardless of maternal varicella immunity), or individuals with immunodeficiencies; theoretical risk of transmission of vaccine virus up to 6 weeks postvaccination<\/li><li>salicylate use within 6 weeks after vaccination; should be avoided<\/li><li>TB, untreated, active or suspected; do not vaccinate until after treatment<\/li><li>TB skin test; temporary depression of test sensitivity; administer test before or simultaneously with MMR vaccine  or unless urgent postpone test until at least 4 weeks after MMR vaccination<\/li><li>thrombocytopenia or history of thrombocytopenic purpura; thrombocytopenia has occurred following primary vaccination with measles vaccine, measles, mumps, and rubella vaccine (MMR), varicella vaccination, and revaccination with measles or MMR II vaccine; evaluate benefit\/risk prior to therapy<\/li><li>report suspected adverse events to Merck &amp; Co. at 1-877-888-4231 or to the Vaccine Adverse Events Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jwe0s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jwe0s3b12","title":"Breast Feeding","mono":"Micromedex:  Infant  risk cannot be ruled out.<br\/>"}]},"4":{"id":"jwe0s4","title":"Drug Interactions","sub":{"1":{"id":"jwe0s4b14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Alemtuzumab (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Aspirin (probable)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Balsalazide (probable)<\/li><li>Benorilate (probable)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Choline Magnesium Trisalicylate (probable)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Meningococcal Vaccine (probable)<\/li><li>Mercaptopurine (established)<\/li><li>Mesalamine (probable)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Olsalazine (probable)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Pneumococcal Vaccine Polyvalent (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Salicylamide (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sodium Thiosalicylate (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Teriflunomide (theoretical)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Trolamine Salicylate (probable)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"jwe0s4b15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Cytomegalovirus Immune Globulin, Human (probable)<\/li><li>Hepatitis B Immune Globulin (probable)<\/li><li>Leflunomide (established)<\/li><li>Rabies Immune Globulin (probable)<\/li><li>Respiratory Syncytial Virus Immune Globulin, Human (probable)<\/li><li>Tetanus Immune Globulin (probable)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><li>Varicella-Zoster Immune Globulin (probable)<\/li><\/ul>"}}},"5":{"id":"jwe0s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (10.7% to 24.4%), Injection site pain (15.9% to 41.1%), Swelling at injection site (8% to 15.6%)<\/li><li><b>Psychiatric:<\/b>Irritability (1% to 6.7%)<\/li><li><b>Other:<\/b>Fever (2.5% to 21.5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome<\/li><li><b>Gastrointestinal:<\/b>Hematochezia<\/li><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Anaphylaxis<\/li><li><b>Neurologic:<\/b>Aseptic meningitis, Encephalitis, Encephalopathy, Febrile seizure, Guillain-Barr  syndrome, Polyneuropathy, Seizure, Subacute sclerosing panencephalitis<\/li><li><b>Ophthalmic:<\/b>Optic neuritis, Retrobulbar neuritis<\/li><li><b>Respiratory:<\/b>Pneumonia, Pneumonitis<\/li><\/ul>"},"6":{"id":"jwe0s6","title":"Drug Name Info","sub":[{"id":"jwe0s6b17","title":"US Trade Names","mono":"ProQuad<br\/>"},{"id":"jwe0s6b18","title":"Synonyms","mono":"<ul><li>Measles, Mumps, Rubella, and Varicella Virus Vaccine, Live<\/li><li>Measles, Mumps, Rubella and Varicella Vaccine Live<\/li><li>MMRV -  Measles, Mumps, Rubella and Varicella Vaccine Live<\/li><\/ul>"},{"id":"jwe0s6b19","title":"Class","mono":"Vaccine<br\/>"},{"id":"jwe0s6b20","title":"Regulatory Status","mono":"RX<br\/>"}]},"9":{"id":"jwe0s9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>reconstitute vial with supplied diluent only, and use immediately or within 30 min of reconstitution<\/li><li>for SubQ use only; do not inject intravascularly<\/li><\/ul>"},"13":{"id":"jwe0s13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to avoid close contact with high-risk individuals susceptible to varicella for up to 6 weeks after vaccination. High-risk individuals include people with compromised immune systems and pregnant women and newborn infants whose mothers have not had chickenpox.<\/li><li>Female patients of childbearing age should avoid getting pregnant for 3 months after receiving vaccination.<\/li><li>Drug may cause fever, irritability, and injection-site pain, erythema, swelling, and rash.<\/li><li>Instruct patient to report a measles-like or varicella-like rash.<\/li><li>Advise parent\/guardian to avoid giving salicylates or aspirin-containing medicine to patient for 6 weeks after vaccination, due to a risk of Reye's syndrome.<\/li><\/ul>"}}}